- Home
- ANL vs IFRX Comparison
ANL vs IFRX Comparison
Compare ANL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- IFRX
- Stock Information
- Founded
- ANL 2004
- IFRX 2007
- Country
- ANL Cayman Islands
- IFRX Germany
- Employees
- ANL N/A
- IFRX N/A
- Industry
- ANL
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- IFRX Health Care
- Exchange
- ANL Nasdaq
- IFRX Nasdaq
- Market Cap
- ANL 61.8M
- IFRX 53.5M
- IPO Year
- ANL 2023
- IFRX 2017
- Fundamental
- Price
- ANL $1.79
- IFRX $1.43
- Analyst Decision
- ANL Hold
- IFRX Strong Buy
- Analyst Count
- ANL 1
- IFRX 5
- Target Price
- ANL N/A
- IFRX $7.40
- AVG Volume (30 Days)
- ANL 11.3K
- IFRX 492.5K
- Earning Date
- ANL 10-21-2025
- IFRX 11-07-2025
- Dividend Yield
- ANL N/A
- IFRX N/A
- EPS Growth
- ANL N/A
- IFRX N/A
- EPS
- ANL N/A
- IFRX N/A
- Revenue
- ANL N/A
- IFRX $191,224.00
- Revenue This Year
- ANL N/A
- IFRX N/A
- Revenue Next Year
- ANL N/A
- IFRX $1,216.24
- P/E Ratio
- ANL N/A
- IFRX N/A
- Revenue Growth
- ANL N/A
- IFRX 54.36
- 52 Week Low
- ANL $1.10
- IFRX $0.71
- 52 Week High
- ANL $3.89
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- ANL 55.55
- IFRX 55.06
- Support Level
- ANL $1.70
- IFRX $1.29
- Resistance Level
- ANL $1.82
- IFRX $1.44
- Average True Range (ATR)
- ANL 0.09
- IFRX 0.14
- MACD
- ANL -0.00
- IFRX -0.00
- Stochastic Oscillator
- ANL 60.33
- IFRX 48.84
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.